Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevelamer carbonate pilot study for phosphate reduction, FGF23 lowering, and vascular function in CKD stage 3
NL-OMON36731Recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Jun 2010
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label, single-arm trial of sevelamer carbonate in chronic kidney disease (CKD), sponsored by Vrije University Medical Center. Primary endpoints: Serum FGF23 change and Phosphaturia change. Started Jun 2010; status: recruiting.
02
Drugs
sevelamer carbonate
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON36731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36731.